biguanides has been researched along with Benign Neoplasms in 28 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Furthermore metformin seems to decrease cancer risk in diabetic patients." | 6.46 | Metformin for aging and cancer prevention. ( Anisimov, VN, 2010) |
| "Preclinical models suggest anticancer activity of IM156, a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS)." | 3.11 | First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. ( Beom, SH; Cheong, JH; Geiger, B; Janku, F; Kim, GM; Kim, HS; Kim, SY; Kim, TW; Lee, YW; Moon, YW; Rha, SY; Rudoltz, MS; Shin, YG; Thurston, A; Welsch, D; Yim, DS; Yoo, S, 2022) |
| "Biguanides are a class of antidiabetic drugs that includes phenformin and metformin; however, the former was withdrawn from approval in many countries due to its toxicity." | 2.72 | Therapeutic Repurposing of Biguanides in Cancer. ( Swanson, KD; Zhao, H; Zheng, B, 2021) |
| "Pertinent to cancer biology is the fact that AMPK is situated in the center of a signaling network involving established tumor suppressors including LKB1, TSC2 and p53." | 2.52 | The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. ( Faubert, B; Jones, RG; Poffenberger, MC; Vincent, EE, 2015) |
| " Herein, a physiologically-based pharmacokinetic (PBPK) and pharmacodynamic framework is proposed for integrating information on physicochemical, cell-based, animal, and human studies of various biguanides to identify gaps in knowledge and to build a systems model that may facilitate the planning of randomized cancer chemoprevention trials of metformin." | 2.48 | A systems pharmacokinetic and pharmacodynamic approach to identify opportunities and pitfalls in energy stress-mediated chemoprevention: the use of metformin and other biguanides. ( Thompson, HJ; Thompson, MD, 2012) |
| "Furthermore metformin seems to decrease cancer risk in diabetic patients." | 2.46 | Metformin for aging and cancer prevention. ( Anisimov, VN, 2010) |
| "The incidence of cancer increases with age in humans and in laboratory animals alike." | 2.45 | Relationships between cancer and aging: a multilevel approach. ( Anisimov, VN; Pawelec, G; Sikora, E, 2009) |
| "A vitamin B12 deficiency is unusual in pregnant women who consume a normal, varied diet." | 2.37 | Clinical chemistry of vitamin B12. ( Davis, RE, 1985) |
| "Metabolic reprogramming in cancer is considered to be one of the most important hallmarks to drive proliferation, angiogenesis, and invasion." | 1.91 | Metformin May Alter the Metabolic Reprogramming in Cancer Cells by Disrupting the L-Arginine Metabolism: A Preliminary Computational Study. ( Arredondo-Espinoza, EU; Balderas-Renteria, I; Carranza-Rosales, P; Espinosa-Rodriguez, BA; Mendez-Lopez, LF; Ramirez-Cabrera, MA; Ramirez-Estrada, K; Treviño-Almaguer, D, 2023) |
| "However, patients with metastatic cancer have a poor prognosis, probably due to the instability, chemoresistance, and inability of albumin-bound paclitaxel to alter the tumor microenvironment." | 1.91 | Biguanide-anchored albumin-based nanoplatform inhibits epithelial-mesenchymal transition and reduces the stemness phenotype for metastatic cancer therapy. ( Chen, J; Chen, Y; Gao, X; Huang, Y; Jiang, T; Wang, J; Xiao, W; Xie, L; Zhou, S, 2023) |
| "In recent years, the anticancer effects of biguanide drugs have received considerable attention." | 1.72 | Synthesis, Anticancer Activities, and Mechanism of N-heptyl-containing Biguanide Derivatives. ( Liu, J; Peng, M; Tang, X; Wang, W; Xiao, D; Xu, C; Xu, S; Yang, X; Zhou, S; Zhou, X, 2022) |
| "This suggests that cancer cells display metabolic plasticity by engaging non-redundant adaptive mechanisms, which allows them to survive therapeutic insults that target cancer metabolism." | 1.48 | Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. ( Avizonis, D; Blouin, MJ; Bridon, G; Cargnello, M; Ferbeyre, G; Ferreira, T; Gravel, SP; Greenwood, C; Hulea, L; Im, YK; Jones, RG; Larsson, O; Lavoie, C; Lehuédé, C; Leibovitch, M; Ma, EH; McLaughlan, S; Morita, M; Muller, W; Ohh, M; Papavasiliou, V; Parisotto, M; Pollak, M; Siegel, P; St-Pierre, J; Topisirovic, I; Uchenunu, O; Ursini-Siegel, J, 2018) |
| "To analyse the association between cancer incidence and oral diabetes therapy (biguanide, sulphonylurea, thiazolidinedione and meglitinide) in men and women with type 2 diabetes mellitus." | 1.40 | Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. ( Kashyap, SR; Kattan, MW; Raghavan, D; Sun, GE; Wells, BJ; Yip, K; Zimmerman, R, 2014) |
| "Notably, the biguanide sensitivity of cancer cells with mtDNA mutations was reversed by ectopic expression of yeast NDI1, a ubiquinone oxidoreductase that allows bypass of complex I function." | 1.40 | Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. ( Bayraktar, EC; Birsoy, K; Chen, WW; Clish, CB; Lorbeer, FK; Possemato, R; Sabatini, DM; Thiru, P; Wang, T; Yucel, B, 2014) |
| " At the same time about 1/3 of these serious adverse drug reactions (ADR) was found to have been reported to the ADR-register." | 1.27 | Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. ( Westerholm, B; Wiholm, BE, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (21.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 7 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, S | 2 |
| Cao, Y | 1 |
| Luo, Y | 1 |
| Xiao, D | 2 |
| Wang, W | 2 |
| Wang, Z | 1 |
| Yang, X | 2 |
| Zhou, S | 2 |
| Tang, X | 1 |
| Zhou, X | 1 |
| Liu, J | 1 |
| Xu, C | 1 |
| Peng, M | 1 |
| Janku, F | 1 |
| Beom, SH | 1 |
| Moon, YW | 1 |
| Kim, TW | 1 |
| Shin, YG | 1 |
| Yim, DS | 1 |
| Kim, GM | 1 |
| Kim, HS | 1 |
| Kim, SY | 1 |
| Cheong, JH | 1 |
| Lee, YW | 1 |
| Geiger, B | 1 |
| Yoo, S | 1 |
| Thurston, A | 1 |
| Welsch, D | 1 |
| Rudoltz, MS | 1 |
| Rha, SY | 1 |
| Espinosa-Rodriguez, BA | 1 |
| Treviño-Almaguer, D | 1 |
| Carranza-Rosales, P | 1 |
| Ramirez-Cabrera, MA | 1 |
| Ramirez-Estrada, K | 1 |
| Arredondo-Espinoza, EU | 1 |
| Mendez-Lopez, LF | 1 |
| Balderas-Renteria, I | 1 |
| Jiang, T | 1 |
| Wang, J | 1 |
| Xie, L | 1 |
| Huang, Y | 1 |
| Chen, Y | 1 |
| Gao, X | 1 |
| Xiao, W | 1 |
| Chen, J | 1 |
| Sakai, T | 1 |
| Matsuo, Y | 1 |
| Okuda, K | 1 |
| Hirota, K | 1 |
| Tsuji, M | 1 |
| Hirayama, T | 1 |
| Nagasawa, H | 1 |
| Zhao, H | 1 |
| Swanson, KD | 1 |
| Zheng, B | 1 |
| Shafiei-Irannejad, V | 1 |
| Samadi, N | 1 |
| Salehi, R | 1 |
| Yousefi, B | 1 |
| Zarghami, N | 1 |
| Hulea, L | 2 |
| Gravel, SP | 2 |
| Morita, M | 1 |
| Cargnello, M | 1 |
| Uchenunu, O | 1 |
| Im, YK | 1 |
| Lehuédé, C | 1 |
| Ma, EH | 1 |
| Leibovitch, M | 1 |
| McLaughlan, S | 1 |
| Blouin, MJ | 2 |
| Parisotto, M | 1 |
| Papavasiliou, V | 1 |
| Lavoie, C | 1 |
| Larsson, O | 1 |
| Ohh, M | 1 |
| Ferreira, T | 1 |
| Greenwood, C | 1 |
| Bridon, G | 1 |
| Avizonis, D | 1 |
| Ferbeyre, G | 1 |
| Siegel, P | 1 |
| Jones, RG | 2 |
| Muller, W | 1 |
| Ursini-Siegel, J | 1 |
| St-Pierre, J | 2 |
| Pollak, M | 4 |
| Topisirovic, I | 2 |
| Sun, GE | 1 |
| Wells, BJ | 1 |
| Yip, K | 1 |
| Zimmerman, R | 1 |
| Raghavan, D | 1 |
| Kattan, MW | 1 |
| Kashyap, SR | 1 |
| Faubert, B | 1 |
| Vincent, EE | 1 |
| Poffenberger, MC | 1 |
| Birsoy, K | 1 |
| Possemato, R | 1 |
| Lorbeer, FK | 1 |
| Bayraktar, EC | 1 |
| Thiru, P | 1 |
| Yucel, B | 1 |
| Wang, T | 1 |
| Chen, WW | 1 |
| Clish, CB | 1 |
| Sabatini, DM | 1 |
| Toban, N | 1 |
| Birman, E | 1 |
| Zakikhani, M | 1 |
| Zhao, Y | 1 |
| Emami-Riedmaier, A | 1 |
| Schaeffeler, E | 1 |
| Nies, AT | 1 |
| Mörike, K | 1 |
| Schwab, M | 1 |
| Pryor, R | 1 |
| Cabreiro, F | 1 |
| Anisimov, VN | 4 |
| Sikora, E | 1 |
| Pawelec, G | 1 |
| Thompson, MD | 1 |
| Thompson, HJ | 1 |
| Berstein, LM | 2 |
| Popovich, IG | 1 |
| Zabezhinski, MA | 1 |
| Egormin, PA | 1 |
| Tyndyk, ML | 1 |
| Anikin, IV | 1 |
| Semenchenko, AV | 1 |
| Yashin, AI | 1 |
| Wiholm, BE | 1 |
| Westerholm, B | 1 |
| Dil'man, VM | 1 |
| Bershteĭn, LM | 1 |
| Tsyrlina, EV | 1 |
| Bobrov, IuF | 1 |
| Kovaleva, IG | 2 |
| Revskoy, SY | 1 |
| Poroshina, TE | 1 |
| Ostroumova, MN | 1 |
| Dilman, VM | 1 |
| Poli, S | 1 |
| Vincent, A | 1 |
| Perret, C | 1 |
| Nazzari, M | 1 |
| Fabbri, C | 1 |
| Zanasi, S | 1 |
| Guidotti, M | 1 |
| Davis, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for biguanides and Benign Neoplasms
| Article | Year |
|---|---|
Therapeutic Repurposing of Biguanides in Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biguanides; Cell Line, Tumor; Clinical Tria | 2021 |
New insights into antidiabetic drugs: Possible applications in cancer treatment.
Topics: AMP-Activated Protein Kinase Kinases; Biguanides; Cell Proliferation; Diabetes Mellitus, Type 2; Hum | 2017 |
Potential applications for biguanides in oncology.
Topics: Antimetabolites, Antineoplastic; Biguanides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Dr | 2013 |
The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Biguanides; Cell Proliferation; | 2015 |
Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?
Topics: Administration, Oral; Biguanides; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Base | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Relationships between cancer and aging: a multilevel approach.
Topics: Age Distribution; Age Factors; Aging; Animals; Anticarcinogenic Agents; Biguanides; Carcinogens; Cel | 2009 |
Metformin and other biguanides in oncology: advancing the research agenda.
Topics: Animals; Antineoplastic Agents; Biguanides; Biomedical Research; Humans; Hypoglycemic Agents; Medica | 2010 |
Metformin for aging and cancer prevention.
Topics: Aging; Animals; Antineoplastic Agents; Biguanides; Caloric Restriction; Humans; Hyperglycemia; Hypog | 2010 |
A systems pharmacokinetic and pharmacodynamic approach to identify opportunities and pitfalls in energy stress-mediated chemoprevention: the use of metformin and other biguanides.
Topics: Animals; Biguanides; Chemoprevention; Energy Metabolism; Humans; Hypoglycemic Agents; Metformin; Neo | 2012 |
Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention.
Topics: Aging; Animals; Biguanides; Cell Transformation, Neoplastic; Humans; Insulin; Insulin-Like Growth Fa | 2003 |
[Lactic acidosis].
Topics: Acidosis; Bicarbonates; Biguanides; Diabetes Mellitus; Epilepsy; Ethanol; Fructose; Heart Failure; H | 1985 |
[Lactic acidosis: review of the principles of physiopathology and treatment].
Topics: Acidosis; Biguanides; Humans; Lactates; Neoplasms; Short Bowel Syndrome | 1985 |
Clinical chemistry of vitamin B12.
Topics: Absorption; Adult; Alcoholism; Anemia, Pernicious; Ascorbic Acid; Autoantibodies; Biguanides; Biolog | 1985 |
1 trial available for biguanides and Benign Neoplasms
| Article | Year |
|---|---|
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
Topics: Antineoplastic Agents; Biguanides; Dose-Response Relationship, Drug; Humans; Maximum Tolerated Dose; | 2022 |
13 other studies available for biguanides and Benign Neoplasms
| Article | Year |
|---|---|
Synthesis, Anti-Proliferative Evaluation and Mechanism of 4-Trifluoro Methoxy Proguanil Derivatives with Various Carbon Chain Length.
Topics: Adenylate Kinase; Antineoplastic Agents; Biguanides; Carbon; Cell Line, Tumor; Cell Proliferation; C | 2021 |
Synthesis, Anticancer Activities, and Mechanism of N-heptyl-containing Biguanide Derivatives.
Topics: Antineoplastic Agents; Benzene; Biguanides; Cell Line, Tumor; Cell Proliferation; Dose-Response Rela | 2022 |
Metformin May Alter the Metabolic Reprogramming in Cancer Cells by Disrupting the L-Arginine Metabolism: A Preliminary Computational Study.
Topics: AMP-Activated Protein Kinases; Antimalarials; Biguanides; Buformin; Creatine; Humans; Metformin; Mol | 2023 |
Biguanide-anchored albumin-based nanoplatform inhibits epithelial-mesenchymal transition and reduces the stemness phenotype for metastatic cancer therapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Biguanides; Cell Line, Tumor; Epithelial-Mesenchymal Tr | 2023 |
Development of antitumor biguanides targeting energy metabolism and stress responses in the tumor microenvironment.
Topics: A549 Cells; Animals; Antineoplastic Agents; Biguanides; Chickens; Energy Metabolism; HEK293 Cells; H | 2021 |
Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.
Topics: Adaptor Proteins, Signal Transducing; Amino Acids; Animals; Antineoplastic Combined Chemotherapy Pro | 2018 |
Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus.
Topics: Benzamides; Biguanides; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; M | 2014 |
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.
Topics: Adenosine Triphosphate; Animals; Biguanides; Cell Culture Techniques; Cell Line, Tumor; Cell Prolife | 2014 |
Serine deprivation enhances antineoplastic activity of biguanides.
Topics: Animals; Biguanides; Cell Line, Tumor; Glycolysis; Humans; Metformin; Mice; Neoplasms; Oxidative Pho | 2014 |
Central and peripheral effects of insulin/IGF-1 signaling in aging and cancer: antidiabetic drugs as geroprotectors and anticarcinogens.
Topics: Aging; Animals; Biguanides; Caenorhabditis elegans Proteins; Caloric Restriction; Humans; Hypoglycem | 2005 |
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
Topics: Acidosis; Aged; Anti-Infective Agents, Urinary; Biguanides; Congenital Abnormalities; Contraceptives | 1984 |
[Correction of endocrine-metabolic disorders in oncologic patients. The effect of biguanides (phenformin and adebita), miskleron and diphenin].
Topics: Adrenal Cortex Hormones; Aged; Biguanides; Blood Glucose; Body Weight; Breast Neoplasms; Buformin; C | 1975 |
Age-dependent metabolic immunodepression and cancer.
Topics: Age Factors; Biguanides; Blood Viscosity; Breast Neoplasms; Cholesterol; Clofibrate; Female; Humans; | 1985 |